Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome

Journal of Controlled Release

Volumn 120, Issue 3, 2007, Pages 169-177

  Yang, Tao ^a,b   Choi, Min Koo ^b   Cui, Fu De ^a   Kim, Jung Sun ^c   Chung, Suk Jae ^b   Shim, Chang Koo ^b   Kim, Dae Duk ^b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Seoul National University   (South Korea)

^c Dongseo University   (South Korea)

Author keywords

Cellular uptake; Herceptin; Paclitaxel; PEGylated immunoliposome

Indexed keywords

CELLULAR UPTAKE; HERCEPTIN; PACLITAXEL; PEGYLATED IMMUNOLIPOSOME;

CELL GROWTH; CONFOCAL MICROSCOPY; ONCOLOGY; PHOSPHOLIPIDS; POLYETHYLENE GLYCOLS; TUMORS;

IMMUNOLOGY;

CREMOPHOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOLIPOSOME; MACROGOL 400; PACLITAXEL; TRASTUZUMAB;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CELL; CONFOCAL MICROSCOPY; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; ENDOCYTOSIS; IN VITRO STUDY; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HALF-LIFE; HUMANS; IMMUNOCONJUGATES; LIPOSOMES; MALE; METABOLIC CLEARANCE RATE; PACLITAXEL; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ERBB-2;

EID: 34447312229     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2007.05.011     Document Type: Article

References (35)

1. Wani M.C., Taylor H.L., Wall M.E., C P., Coggon A.T., and McPhail. Plant antitumor agents, VI: the isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93 (1971) 2325-2327
2. Chang A.Y., Rubins J., Asbury R., Boros L., and Hui L.F. Weekly paclitaxel in advanced non-small cell lung cancer. Semi. Oncol. 28 (2001) 10-13
3. Ishitobi M., Shin E., and Kikkawa N. Metastatic breast cancer with resistance to both anthracycline and docetaxel successfully treated with weekly paclitaxel. Int. J. Clin. Oncol. 6 (2001) 55-58
4. Gelderblom H., Verweij J., Nooter K., and Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37 (2001) 1590-1598
5. Zhang J.A., Anyarambhatla G., Ma L., Ugwu S., Xuan T., Sardone T., and Ahmad I. Development and characterization of a novel CremophorÒEL free liposome-based paclitaxel (LEP-ETU) formulation. Eur. J. Pharm. Biopharm. 59 (2005) 177-187
6. Bally M.B., Lim H., Cullis P.R., and Mayer L.D. Controlling the drug delivery attributes of lipid-based drug formulations. J. Liposome Res. 8 (1998) 299-335
7. Lundberg B. The solubilization of lipophilic derivatives of podophyllotoxins in sub-micron sized lipid emulsions and their cytotoxic activity against cancer cells in culture. Int. J. Pharm. 109 (1994) 73-81
8. Lundberg B.B., Griffiths G., and Hansen H.J. Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells. J. Control. Release 94 (2004) 155-161
9. Torchilin V.P., and Trubetskoy V.S. Which polymers can make nanoparticulate drug carriers long-circulating?. Adv. Drug Deliv. Rev. 16 (1995) 141-155
10. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., and Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55 (1995) 3752-3756
11. Laginha K., Mumbengegwi D., and Allen T. Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity. Biochim. Biophys. Acta 1711 (2005) 25-32
12. Suzuki S., Watanabe S., Masuko T., and Hashimoto Y. Preparation of long-circulating immunoliposomes containing adriamycin by a novel method to coat immunoliposomes with polyethylene glycol. Biochem. Biophys. Acta 1245 (1995) 22-29
13. Nam S.M., Kim H.S., Ahn W.S., and Park Y.S. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells. Oncol. Res. 11 (1999) 9-16
14. Pagnan G., Montaldo P.G., Pastorino F., Raffaghello L., Kirchmeier M., and Allen T.M. GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int. J. Cancer 81 (1999) 268-274
15. Reddy K.R. Controlled-release, pegylation, liposomal formulation: new mechanisms in the delivery of injectable drugs. Drug Deliv. 34 (2000) 915-923
16. Hynes N.E., and Stern D.F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta 1198 (1994) 165-184
17. D. Slamon, Herceptin®: increasing survival in metastatic breast cancer, European Journal of Oncology Nursing 4 (Suppl 1) 24-29.
18. Ito A., Kuga Y., Honda H., Kikkawa H., Horiuchi A., Watanabe Y., and Kobayashi T. Magnetic nanoparticle-loaded anti-immunoliposomes for combination of antibody therapy with hyperthermia. Cancer lett. 212 (2004) 167-175
19. Park J.W., Hong K., Carter P., Asgari H., Guo L.Y., Keller G.A., et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. 92 (1995) 1327-1331
20. Park J.W., Kirpotin D.B., Hong K., Shalaby R., Shao Y., Nielsen U.B., Marks J.D., Papahadjopoulos D., and Benz C.C. Tumor targeting using anti-her2 immunoliposomes. J. Control. Release 74 (2001) 95-113
21. Lewis G.D., Figari I., Fendly B., Wong W.L., Carter P., Gorman C., and Shepard H.M. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37 (1993) 255-263
22. Yang T., Cui F.D., Choi M.K., Cho J.W., Chung S.J., Shim C.K., and Kim D.D. Enhanced solubility and stability of PEGylated liposomal paclitaxel: In vitro and in vivo evaluation. Int. J. Pharm. 338 (2007) 317-326
23. Nielsen U.B., Kirpotin D.B., Pickering E.M., Hong K., Park J.W., Shalaby M.R., Shao Y., Benz C.C., and Marks J.D. Therapeutic efficacy of anti-ErbB2 immnoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim. Biophys. Acta 1591 (2002) 109-118
24. T. Yang, F.D. Cui, M.K. Choi, H.X. Lin, S.J. Chung, C.K. Shim, D.D. Kim, Liposome formulation of paclitaxel with enhanced solubility and stability, Drug Delivery (in press), doi:10.1080/10717540601098799.
25. 111In-trastuzumab (Herceptin) Fab fragments. Nucl. Med. Biol. 32 (2005) 51-58
26. Maeda N., Takeuchi Y., Takada M., Sadzuka Y., Namba Y., and Oku N. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J. Control. Release 100 (2004) 41-52
27. Koziara J.M., Lockman P.R., Allen D.D., and Mumper R.J. Paclitaxel nanoparticles for the potential treatment of brain tumor. J. Control. Release 99 (2004) 259-269
28. Kim K.E., Cho W.J., Chang S.J., Yong C.S., Lee C.H., and Kim D.D. Pharmacokinetics of a new antitumor 3-arylisoquinoline derivative, CWJ-a-5. Int. J. Pharm. 217 (2001) 101-110
29. Sparreboom A., Tellingen O.V., Nooijen W.J., and Beijnen J.H. Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high performance liquid chromatography. J. Chromatogr. 664 (1995) 383-391
30. Hansen C.B., Kao G.Y., Moase E.H., Zalipsky S., and Allen T.M. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta 1239 (1995) 133-144
31. Lu J., Jeon E., Lee B.S., Onyuksel H., and Wang Z.J. Targeted drug delivery crossing cytoplasmic membranes of intended cells via ligand-grafted sterically stabilized liposomes. J. Control. Release 110 (2006) 505-513
32. Xu Z.H., Gu W.W., Huang J., Sui H., Zhou Z.H., Yang Y.X., Yan Z., and Li Y.P. In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery. Int. J. Pharm. 288 (2005) 361-368
33. Moreira J.N., Gaspar R., and Allen T.M. Targeting Stealth liposomes in a mutine model of human small cell lung cancer. Biochim. Biophys. Acta 1515 (2001) 167-176
34. Maruyama K. PEG-Immunoliposome. Biosci. Rep. 22 (2002) 251-266
35. Harding J.A., Engbers C.M., Newman M.S., Goldstein N.I., and Zalipsky S. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim. Biophys. Acta. 1327 (1997) 181-192